Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

SELECTED QUARTERLY FINANCIAL DATA (Tables)

12 Months Ended

Dec. 31, 2012

	(unaudited, in thousands, except per share amounts)

	Year Ended December 31, 2012												Year Ended December 31, 2011
	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
Revenue	$	750		$	1,500		$	—		$	—		$	—		$	395		$	4,355		$	—
Net loss	$	(23,174	)	$	(24,738	)	$	(25,456	)	$	(25,472	)	$	(20,781	)	$	(21,474	)	$	(17,931	)	$	(25,787	)
Net loss per share, basic and diluted	$	(0.32	)	$	(0.35	)	$	(0.36	)	$	(0.30	)	$	(0.40	)	$	(0.37	)	$	(0.25	)	$	(0.36	)
Weighted average shares used in computing net loss per share, basic and diluted		71,422			71,458			71,636			85,274			52,275			58,272			71,226			71,249